Skip to main content

Advertisement

Table 1 Patient characteristics

From: Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

  Total (n = 94) CC (n = 46) CP (n = 48)
Age, years    
Median (range) 63 (34–82) 62 (46–76) 63 (34–82)
Gender    
Male 92 45 47
Female 2 1 1
Smoking history    
Never 7 5 2
Current or former 85 39 46
Prior therapy    
Surgery 31 15 16
Radiotherapy 20 10 10
Chemotherapy (adjuvant or neoadjuvant) 19 9 10
Initial disease status    
Initial advanced state 59 29 30
Recurred state 35 17 18
Locoregional disease 4 3 1
Distant metastasis 90 43 47
No. of metastatic sites    
One 45 24 21
Two or more 49 22 27
Metastatic sites    
Neck, supraclavicular LN 51 24 27
Abdominal LN 42 23 19
Lung 30 10 20
Bone 17 8 9
Liver 12 6 6
  1. CC capecitabine plus cisplatin, CP, capecitabine plus paclitaxel, ECOG, Eastern Cooperative Oncology Group, LN, lymph nodes